These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11462924)

  • 1. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
    Kubicka S; Rudolph KL; Tietze MK; Lorenz M; Manns M
    Hepatogastroenterology; 2001; 48(39):783-9. PubMed ID: 11462924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
    Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
    Fuchs CS; Clark JW; Ryan DP; Kulke MH; Kim H; Earle CC; Vincitore M; Mayer RJ; Stuart KE
    Cancer; 2002 Jun; 94(12):3186-91. PubMed ID: 12115351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
    Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
    Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver.
    Kirchhoff T; Zender L; Merkesdal S; Frericks B; Malek N; Bleck J; Kubicka S; Baus S; Chavan A; Manns MP; Galanski M
    World J Gastroenterol; 2005 Feb; 11(8):1091-5. PubMed ID: 15754387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
    Yang TS; Lin YC; Chen JS; Wang HM; Wang CH
    Cancer; 2000 Aug; 89(4):750-6. PubMed ID: 10951336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Schüll B; Raderer M; Scheithauer W
    Oncology; 2001; 60(4):313-5. PubMed ID: 11408798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.
    Parikh PM; Fuloria J; Babu G; Doval DC; Awasthy BS; Pai VR; Prabhakaran PS; Benson AB
    Trop Gastroenterol; 2005; 26(3):115-8. PubMed ID: 16512457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
    Sohal DP; Mykulowycz K; Uehara T; Teitelbaum UR; Damjanov N; Giantonio BJ; Carberry M; Wissel P; Jacobs-Small M; O'Dwyer PJ; Sepulveda A; Sun W
    Ann Oncol; 2013 Dec; 24(12):3061-5. PubMed ID: 24146220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
    Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
    Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).
    Inaba Y; Arai Y; Yamaura H; Sato Y; Najima M; Aramaki T; Sone M; Kumada T; Tanigawa N; Anai H; Yoshioka T; Ikeda M;
    Am J Clin Oncol; 2011 Feb; 34(1):58-62. PubMed ID: 20177362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
    Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.
    Guan Z; Wang Y; Maoleekoonpairoj S; Chen Z; Kim WS; Ratanatharathorn V; Reece WH; Kim TW; Lehnert M
    Br J Cancer; 2003 Nov; 89(10):1865-9. PubMed ID: 14612894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is there a nonsurgical therapeutic approach to cholangiocellular carcinomas?].
    Fuchs M; Schepp W
    Chirurg; 2006 Apr; 77(4):341-51. PubMed ID: 16534617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
    Yu ZY; Ouyang XN; Chen ZS; Li J; Chen X; Xie FW
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):144-6. PubMed ID: 18646701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.